Related Experiment Video
Updated: Aug 2, 2025

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway
Lijie Dong1, Rui Cheng2,3, Xiang Ma2,3
1Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Abstract:
Monocyte activation plays an important role in diabetic complications such as diabetic retinopathy (DR). However, the regulation of monocyte activation in diabetes remains elusive. Fenofibrate, an agonist of peroxisome proliferator-activated receptor-α (PPARα), has shown robust therapeutic effects on DR in patients with type 2 diabetes. Here we found that PPARα levels were significantly downregulated in monocytes from patients with diabetes and animal models, correlating with monocyte activation. Fenofibrate attenuated monocyte activation in diabetes, while PPARα knockout alone induced monocyte activation. Furthermore, monocyte-specific PPARα overexpression ameliorated, while monocyte-specific PPARα knockout aggravated monocyte activation in diabetes. PPARα knockout impaired mitochondrial function while also increasing glycolysis in monocytes. PPARα knockout increased cytosolic mitochondrial DNA release and activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in monocytes under diabetic conditions. STING knockout or STING inhibitor attenuated monocyte activation induced by diabetes or by PPARα knockout. These observations suggest that PPARα negatively regulates monocyte activation through metabolic reprogramming and interaction with the cGAS-STING pathway.
Insights
Peroxisome proliferator-activated receptor-α (PPARα) deficiency activates monocytes in diabetes, contributing to diabetic complications. Restoring PPARα function may offer a therapeutic strategy for diabetic retinopathy.
Area of Science:
- Immunology
- Metabolic Disorders
- Ophthalmology
Background:
- Monocyte activation is implicated in diabetic complications like diabetic retinopathy (DR).
- The regulatory mechanisms of monocyte activation in diabetes are not fully understood.
- Fenofibrate, a peroxisome proliferator-activated receptor-α (PPARα) agonist, shows therapeutic potential for DR.
Purpose of the Study:
- To investigate the role of PPARα in regulating monocyte activation in diabetes.
- To elucidate the molecular pathways linking PPARα to monocyte activation under diabetic conditions.
Main Methods:
- Assessed PPARα levels in monocytes from diabetic patients and animal models.
- Utilized PPARα knockout and overexpression models in monocytes.
- Analyzed mitochondrial function and glycolysis.
- Investigated the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway.
Main Results:
- PPARα levels were downregulated in diabetic monocytes, correlating with activation.
- PPARα deficiency exacerbated monocyte activation, impaired mitochondrial function, and increased glycolysis.
- PPARα deficiency led to cytosolic mitochondrial DNA release and cGAS-STING pathway activation.
- Targeting the STING pathway attenuated diabetes-induced monocyte activation.
Conclusions:
- PPARα acts as a negative regulator of monocyte activation in diabetes.
- PPARα influences monocyte activation via metabolic reprogramming (mitochondria and glycolysis).
- The cGAS-STING pathway is a key mediator in PPARα-regulated monocyte activation during diabetes.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Differentiation of Common Myeloid Progenitor Cells
Master Transcription Regulators
Global Regulatory Systems
The JAK-STAT Signaling Pathway
Regulation of Hematopoietic Stem Cells

